Researchers from Karolinska Institute Report Recent Findings in Chronic Lymphocytic Leukemia (Risk-adapted Bendamustine Plus Rituximab Is a Tolerable Treatment Alternative for Elderly Patients With Chronic Lymphocytic Leukaemia: a Regional …)
2021 JAN 18 (NewsRx) -- By a
Financial supporters for this research include
Our news editors obtained a quote from the research from
According to the news editors, the research concluded: “In summary, BR was well tolerated even in patients >= 80 years, with similar efficacy and safety as in less old patients, provided that carefully adapted dosing was applied.”
This research has been peer-reviewed.
For more information on this research see: Risk-adapted Bendamustine Plus Rituximab Is a Tolerable Treatment Alternative for Elderly Patients With Chronic Lymphocytic Leukaemia: a Regional Real-world Report On 141 Consecutive Swedish Patients.
The news editors report that additional information may be obtained by contacting
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1111/bjh.17032. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)
China Economy Grows In 2020 As Rebound From Virus Gains
FEMA Provides an Additional $181 Million to Colorado for COVID-19 Response
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News